Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer (CROSS Trial)
Source: View publication →
Neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel followed by surgery significantly improved overall survival compared to surgery alone in patients with potentially curable esophageal or esophagogastric-junction cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CROSS trial is a landmark study that firmly established neoadjuvant chemoradiotherapy using carboplatin and paclitaxel as a standard of care for locally advanced, resectable esophageal and esophagogastric-junction cancers. By achieving high rates of R0 resection and nearly doubling median overall survival without increasing surgical morbidity or mortality, this well-tolerated regimen revolutionized the multimodality management of upper gastrointestinal malignancies.
Historical Context
Prior to the CROSS trial, the prognosis for locally advanced esophageal cancer managed with surgery alone was poor, plagued by high rates of local recurrence and positive margins. Earlier neoadjuvant trials yielded mixed results and often utilized highly toxic chemotherapy regimens (like cisplatin and fluorouracil) combined with higher-dose radiation, which increased postoperative complications. By introducing a well-tolerated, lower-toxicity regimen with moderate-dose radiation, the CROSS trial demonstrated a profound survival benefit, cementing trimodality therapy as the dominant therapeutic strategy in the Western world.
Guided Discussion
High-yield insights from every perspective
The CROSS trial included patients with both squamous cell carcinomas and adenocarcinomas of the esophagus. What are the key risk factors and typical anatomical locations for these two histological subtypes, and what is the basic mechanistic rationale for using chemoradiotherapy before surgery (neoadjuvant) rather than after?
Key Response
This question tests foundational knowledge. Adenocarcinomas typically arise in the distal esophagus/EG junction and are linked to GERD and Barrett's esophagus. Squamous cell carcinomas often occur in the proximal/mid-esophagus and are strongly associated with smoking and alcohol use. Neoadjuvant therapy is mechanistically favored to downstage the tumor, increase the likelihood of achieving negative surgical margins (R0 resection), and eradicate early micrometastatic disease while the local blood supply is intact.
In the CROSS trial, the neoadjuvant regimen utilized a backbone of weekly carboplatin and paclitaxel. How does this specific regimen compare in terms of toxicity and tolerability to historical regimens (like cisplatin/5-FU), and which specific patient populations are indicated for this approach?
Key Response
Residents must understand the practical clinical application of this trial. The CROSS regimen (carboplatin/paclitaxel) is significantly better tolerated with lower rates of severe hematologic and gastrointestinal toxicities compared to older cisplatin/5-fluorouracil regimens. It is indicated for patients with locally advanced, resectable (T1N1 or T2-3N0-1) esophageal or EGJ cancer, balancing excellent tumor downstaging with a safety profile that does not significantly increase postoperative mortality.
The CROSS trial demonstrated a significantly higher pathologic complete response (pCR) rate in squamous cell carcinomas (49%) compared to adenocarcinomas (23%). How does this differential radiosensitivity influence the modern consideration of definitive chemoradiotherapy (organ preservation) for SCC, and what recent phase 3 data dictates adjuvant management for patients who do not achieve a pCR?
Key Response
Fellows must integrate CROSS with modern paradigms. The high pCR rate in SCC has sparked trials evaluating active surveillance (surgery only for salvage) to spare patients esophagectomy morbidity (e.g., SANO trial concepts). Furthermore, fellows should know that based on the CheckMate 577 trial, patients who receive CROSS nCRT followed by surgery but fail to achieve a pCR should be offered adjuvant nivolumab, representing a major paradigm shift in multidisciplinary management.
While the CROSS trial established neoadjuvant chemoradiotherapy as a standard of care without increasing 30-day postoperative mortality in a controlled trial setting, how do you navigate the real-world risks of radiation-induced pulmonary complications and anastomotic leaks in older, frailer patients undergoing complex esophagectomies?
Key Response
Attendings must bridge the gap between trial efficacy and real-world effectiveness. Delivering 41.4 Gy of radiation prior to an Ivor Lewis or McKeown esophagectomy can lead to tissue fibrosis and impair anastomotic healing. The attending must thoughtfully weigh oncologic benefit against surgical morbidity, potentially modifying the radiation field, adjusting surgical techniques (e.g., omental flaps), or reconsidering the surgical candidacy of frail patients post-CRT.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The CROSS trial was powered to detect a survival difference in the overall cohort, combining adenocarcinomas and squamous cell carcinomas despite their distinct biological behaviors and pCR rates. What are the methodological limitations and potential statistical confounding effects of combining these two distinct diseases into a single primary efficacy endpoint, and how would you design a translational study to untangle the drivers of radioresistance in the adenocarcinoma subgroup?
Key Response
This challenges PhDs to critique study design and heterogeneity. Lumping distinct histologies to achieve statistical power can obscure subtype-specific effects; for instance, the immense benefit in SCC might pull the overall survival curve, potentially masking a more modest benefit in adenocarcinoma. A follow-up translational design would require genomic/transcriptomic profiling of pre-treatment adenocarcinoma biopsies to identify biomarkers of radioresistance (e.g., hypoxia signatures, DNA repair mutations) compared to SCC.
A critical reviewer examining the CROSS trial might note that the R0 resection rate in the surgery-alone arm was only 69%. How does this relatively low R0 rate in the control group affect the internal validity and the magnitude of the reported survival benefit of the neoadjuvant chemoradiotherapy arm?
Key Response
Editors focus on threats to validity and the performance of the control arm. An R0 rate of 69% in the surgery-alone arm is considered suboptimal by modern, high-volume center standards. A tough reviewer would flag that if the surgical control group underperformed (leaving residual microscopic disease in 31% of patients), the relative benefit of the neoadjuvant arm (which had a 92% R0 rate) might be exaggerated, raising questions about whether better baseline surgical quality could have narrowed the survival gap.
For adenocarcinomas of the esophagogastric junction (Siewert types I and II), current NCCN and ESMO guidelines support both the CROSS regimen (neoadjuvant chemoradiotherapy) and the FLOT regimen (perioperative chemotherapy). How should a guideline committee grade the evidence and provide recommendations to guide multidisciplinary selection between these two distinct approaches, particularly in light of recent comparative trials like ESOPEC?
Key Response
Guideline committees constantly grapple with overlapping, high-level evidence for competing regimens. Historically, CROSS and FLOT were both Category 1 recommendations without a definitive head-to-head overall survival read-out. A committee must weigh surgical morbidity (radiation effects of CROSS) versus systemic toxicity (FLOT). With recent presentations of trials like ESOPEC showing an overall survival advantage for FLOT in operable adenocarcinomas, guidelines must adapt, potentially shifting CROSS to a preferred option only for SCC or margin-threatened bulky EGJ tumors.
Clinical Landscape
Noteworthy Related Trials
MAGIC Trial
Tested
Perioperative ECF chemotherapy
Population
Patients with resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus
Comparator
Surgery alone
Endpoint
Overall survival
FLOT4-AIO Trial
Tested
Perioperative FLOT chemotherapy
Population
Patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma
Comparator
Perioperative ECF or ECX chemotherapy
Endpoint
Overall survival
CheckMate 577
Tested
Adjuvant nivolumab for 1 year
Population
Patients with resected esophageal or gastroesophageal junction cancer with residual pathologic disease after neoadjuvant chemoradiotherapy
Comparator
Placebo
Endpoint
Disease-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis